Mesavance regulatory update

SHP submitted an NDA to FDA for Mesavance mesalamine to treat active, mild to moderate ulcerative colitis (UC). SHP expects to submit an MAA this quarter. SHP licensed from Giuliani SpA (Milan, Italy)...